Theralase(R) Engages Global One Media to Expand Global Investor Awareness

About this update from Theralase Technologies Inc.

Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. ("Global One Media") to provide digital investor marketing and communications services to the Company. Global One Media is an arm's-length investor marketing firm headquartered in Singapore that specializes in digital investor communications for publicly traded companies. Its services include strategic messaging, video production, social media communications and international distribution across investor-focused media channels. Commencing August 1, 2026, Global One Media will assist Theralase® with an investor awareness program designed to increase the Company's visibility and communicate its corporate, scientific and clinical developments to investors across North America, Europe and Asia. Services may include social media management and distribution, digital distribution of Company news releases, content creation, executive interviews, podcasts, corporate video production, investor-focused media features, panel discussions and targeted digital advertising. All distributed materials concerning Theralase® will be based on the Company's publicly disclosed information and will be subject to the Company's prior review and approval. Under the agreement, Global One Media will receive a cash fee compensation of US$39,000 for a six-month term. Global One Media will not receive any securities as compensation. To the Company's knowledge, neither Global One Media nor its principals currently have any direct or indirect interest in the securities of Theralase® or any right or intention to acquire such an interest. The engagement is subject to customary filings and acceptance by the TSX Venture Exchange. Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase®, stated, "As Theralase® continues to advance its clinical, regulatory and commercialization objectives, effectively communicating our progress to a broader international investor audience remains an important priority. Global One Media's digital communication cap...

View stock analysis, news, and events for Theralase Technologies Inc.